Bris­tol My­ers de­tails PhI­II win in first-line test of Re­blozyl for re­duc­ing trans­fu­sions in ear­ly blood can­cer pa­tients

Re­blozyl, a drug that spurs bone mar­row to make more blood cells, helped near­ly twice as many ane­mic pa­tients with an ear­ly form of blood can­cer pro­long the need for trans­fu­sions com­pared to those who got an old­er ther­a­py.

The re­sults, which Bris­tol My­ers Squibb an­nounced Thurs­day evening, had been pre­vi­ous­ly teased from a Phase III study called COM­MANDS, which test­ed Re­blozyl as a first-line treat­ment in about 350 adults with very low to in­ter­me­di­ate risk myelodys­plas­tic syn­drome, or MDS, a blood can­cer that pre­vents red blood cells from ma­tur­ing and can progress in­to leukemia.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN